Chimovits Erez bought BRVE

August 7, 2026 · Form 4 insider transaction

Chimovits Erez bought 273,333 shares of Braveheart Bio, Inc. at $18.00 per share, a transaction worth $4.92M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.

Direction
Acquired (buy-side)
Shares
273,333
Price
$18.00
Total value
$4.92M
RoleDirector
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateAugust 7, 2026
Filing dateAugust 11, 2026
Shares owned after273,333
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.; These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by Genesis.; Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR
Chimovits Erez bought BRVE: August 7, 2026 | Insider Trading Screener